Skip to content

Study · Non-randomized trial · n = 24 · 1985

16 results

Ovulation inhibition with nafarelin acetate nasal administration for six months.

Brenner PF, Shoupe D, Mishell DR Jr

Contraception1 Dec 1985Cited by 7 (Europe PMC)

PMID2936564 (opens in a new tab)DOI10.1016/s0010-7824(85)80001-9 (opens in a new tab)PepBankPUB-02936564
Publisher pagePubMedAsk about this study
Jump to 16 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study16

16 results from studies that gave the peptide. 16 results from people.

  1. 01HumanNon-randomized trialSafety outcome

    In women receiving nafarelin, two subjects did not complete treatment.

    In plain wordsIn women receiving nafarelin, two subjects did not complete treatment.

    Peptide
    Nafarelin
    Outcome
    Not applicableTreatment noncompletion
    Study

    n = 24

    Outcome group
    Adverse events · Whole body
    Studied dose
    125 or 250 micrograms daily · intranasal · 6 monthsAs given in this study (human).

    Measurements

    Subjects not completing treatment
    2 subjects
    of 24 women, treatment phase

    Source sentences

    Summary
    Two subjects failed to complete the treatment phase.
    2 context sentences
    Summary · context
    A group of 24 women with normal menstrual cycles were treated with nafarelin acetate administered in doses of either 125 micrograms or 250 micrograms daily intranasally for 6 months.
    Summary · context
    Each subject was studied for one ovulatory control cycle, six treatment cycles, and post-treatment until the return of ovulation was documented.
  2. 02HumanNon-randomized trialSafety outcome

    In women receiving nafarelin, galactorrhea occurred in 2 subjects.

    In plain wordsIn women receiving nafarelin, galactorrhea occurred in 2 subjects.

    Peptide
    Nafarelin
    Outcome
    Not applicableGalactorrhea
    Study

    n = 24

    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    125 or 250 micrograms daily · intranasal · 6 monthsAs given in this study (human).

    Measurements

    Subjects with galactorrhea
    2 subjects
    nafarelin-treated women

    Source sentences

    Summary
    Side effects observed during this study included galactorrhea (2 subjects) and vasomotor symptoms (7 subjects).
    2 context sentences
    Summary · context
    A group of 24 women with normal menstrual cycles were treated with nafarelin acetate administered in doses of either 125 micrograms or 250 micrograms daily intranasally for 6 months.
    Summary · context
    Each subject was studied for one ovulatory control cycle, six treatment cycles, and post-treatment until the return of ovulation was documented.
  3. 03HumanNon-randomized trialSafety outcome

    In women receiving nafarelin, vasomotor symptoms occurred in 7 subjects.

    In plain wordsIn women receiving nafarelin, vasomotor symptoms occurred in 7 subjects.

    Peptide
    Nafarelin
    Outcome
    Not applicableVasomotor symptoms
    Study

    n = 24

    Outcome group
    Adverse events · Whole body
    Studied dose
    125 or 250 micrograms daily · intranasal · 6 monthsAs given in this study (human).

    Measurements

    Subjects with vasomotor symptoms
    7 subjects
    nafarelin-treated women

    Source sentences

    Summary
    Side effects observed during this study included galactorrhea (2 subjects) and vasomotor symptoms (7 subjects).
    2 context sentences
    Summary · context
    A group of 24 women with normal menstrual cycles were treated with nafarelin acetate administered in doses of either 125 micrograms or 250 micrograms daily intranasally for 6 months.
    Summary · context
    Each subject was studied for one ovulatory control cycle, six treatment cycles, and post-treatment until the return of ovulation was documented.
  4. 04HumanNon-randomized trialSafety outcome

    In women receiving nafarelin at 250 micrograms daily, one stopped on the sixth day because of heavy uterine bleeding.

    In plain wordsIn women receiving nafarelin at 250 micrograms daily, one stopped on the sixth day because of heavy uterine bleeding.

    Peptide
    Nafarelin
    Outcome
    Not applicableHeavy uterine bleeding discontinuation
    Study

    n: not reported in source

    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    250 micrograms daily · intranasal · sixth dayAs given in this study (human).

    Measurements

    Subjects discontinuing for heavy uterine bleeding
    1 subject
    250 micrograms daily
    Day of discontinuation
    6 day
    250 micrograms daily

    Source sentences

    Summary
    One subject using the 250 micrograms daily dose of nafarelin acetate discontinued treatment on the sixth day because of heavy uterine bleeding.
    2 context sentences
    Summary · context
    A group of 24 women with normal menstrual cycles were treated with nafarelin acetate administered in doses of either 125 micrograms or 250 micrograms daily intranasally for 6 months.
    Summary · context
    Each subject was studied for one ovulatory control cycle, six treatment cycles, and post-treatment until the return of ovulation was documented.
  5. 05HumanNon-randomized trialSafety outcome

    In women receiving nafarelin at 125 micrograms daily, one stopped on day 126 because of a 21-pound weight gain.

    In plain wordsIn women receiving nafarelin at 125 micrograms daily, one stopped on day 126 because of a 21-pound weight gain.

    Peptide
    Nafarelin
    Outcome
    IncreaseWeight gain discontinuation
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    125 micrograms daily · intranasal · 126 daysAs given in this study (human).

    Measurements

    Weight gain
    21 pounds
    125 micrograms daily
    Day of discontinuation
    126 day
    125 micrograms daily

    Source sentences

    Summary
    One subject using the 125 micrograms daily dose of the study drug terminated treatment on day 126 because of a 21-pound weight gain.
    2 context sentences
    Summary · context
    A group of 24 women with normal menstrual cycles were treated with nafarelin acetate administered in doses of either 125 micrograms or 250 micrograms daily intranasally for 6 months.
    Summary · context
    Each subject was studied for one ovulatory control cycle, six treatment cycles, and post-treatment until the return of ovulation was documented.
  6. 06HumanNon-randomized trialEfficacy outcome

    In women, presumed ovulation occurred in 2 of 60 cycles with higher-dose nafarelin versus 10 of 54 with lower-dose nafarelin.

    In plain wordsIn women, presumed ovulation was less frequent with higher-dose nafarelin than lower-dose nafarelin.

    Peptide
    Nafarelin
    Outcome
    DecreasePresumed ovulatory cycles
    Study

    n: not reported in source

    Comparator
    125 micrograms daily nafarelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    250 micrograms daily · intranasal · 6 monthsAs given in this study (human).

    Measurements

    Presumed ovulatory cycles
    2 cycles
    250 micrograms daily, of 60 cycles
    Presumed ovulatory cycles
    10 cycles
    125 micrograms daily, of 54 cycles

    Source sentences

    Summary
    There were significantly less presumed ovulatory cycles at the higher dose (2 out of 60 cycles) than at the lower dose (10 out of 54 cycles) (p less than 0.01).
    2 context sentences
    Summary · context
    A group of 24 women with normal menstrual cycles were treated with nafarelin acetate administered in doses of either 125 micrograms or 250 micrograms daily intranasally for 6 months.
    Summary · context
    Each subject was studied for one ovulatory control cycle, six treatment cycles, and post-treatment until the return of ovulation was documented.
  7. 07HumanNon-randomized trialEfficacy outcome

    In women, menstrual cycles returned 28.5 +/- 8.3 days after nafarelin at 125 micrograms daily stopped.

    In plain wordsIn women, menstrual cycles returned an average of 28.5 days after nafarelin at 125 micrograms daily stopped.

    Peptide
    Nafarelin
    Outcome
    Not applicableMenstrual cycle return
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    125 micrograms daily · intranasal · 6 monthsAs given in this study (human).

    Measurements

    Time to menstrual cycle reestablishment, mean
    28.5 days
    after stopping 125 micrograms daily
    Time to menstrual cycle reestablishment, SD
    8.3 days
    after stopping 125 micrograms daily

    Source sentences

    Summary
    On the average menstrual cycles were reestablished 28.5 +/- 8.3 (S.D.) days after discontinuing the 125 micrograms daily dose and 33.7 +/- 17.9 (S.D.) days after terminating the 250 micrograms daily dose.
    2 context sentences
    Summary · context
    A group of 24 women with normal menstrual cycles were treated with nafarelin acetate administered in doses of either 125 micrograms or 250 micrograms daily intranasally for 6 months.
    Summary · context
    Each subject was studied for one ovulatory control cycle, six treatment cycles, and post-treatment until the return of ovulation was documented.
  8. 08HumanNon-randomized trialEfficacy outcome

    In women, menstrual cycles returned 33.7 +/- 17.9 days after nafarelin at 250 micrograms daily stopped.

    In plain wordsIn women, menstrual cycles returned an average of 33.7 days after nafarelin at 250 micrograms daily stopped.

    Peptide
    Nafarelin
    Outcome
    Not applicableMenstrual cycle return
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    250 micrograms daily · intranasal · 6 monthsAs given in this study (human).

    Measurements

    Time to menstrual cycle reestablishment, mean
    33.7 days
    after stopping 250 micrograms daily
    Time to menstrual cycle reestablishment, SD
    17.9 days
    after stopping 250 micrograms daily

    Source sentences

    Summary
    On the average menstrual cycles were reestablished 28.5 +/- 8.3 (S.D.) days after discontinuing the 125 micrograms daily dose and 33.7 +/- 17.9 (S.D.) days after terminating the 250 micrograms daily dose.
    2 context sentences
    Summary · context
    A group of 24 women with normal menstrual cycles were treated with nafarelin acetate administered in doses of either 125 micrograms or 250 micrograms daily intranasally for 6 months.
    Summary · context
    Each subject was studied for one ovulatory control cycle, six treatment cycles, and post-treatment until the return of ovulation was documented.
  9. 09HumanNon-randomized trialEfficacy outcome

    In women, higher-dose nafarelin produced significantly fewer bleeding episodes than lower-dose nafarelin.

    In plain wordsIn women, higher-dose nafarelin produced fewer bleeding episodes than lower-dose nafarelin.

    Peptide
    Nafarelin
    Outcome
    DecreaseBleeding episodes
    Study

    n: not reported in source

    Comparator
    125 micrograms daily nafarelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    250 micrograms daily · intranasal · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    With the higher dose of nafarelin acetate there were significantly fewer bleeding episodes, less number of days of bleeding, and longer cycles.
    2 context sentences
    Summary · context
    A group of 24 women with normal menstrual cycles were treated with nafarelin acetate administered in doses of either 125 micrograms or 250 micrograms daily intranasally for 6 months.
    Summary · context
    Each subject was studied for one ovulatory control cycle, six treatment cycles, and post-treatment until the return of ovulation was documented.
  10. 10HumanNon-randomized trialEfficacy outcome

    In women, higher-dose nafarelin produced significantly fewer bleeding days than lower-dose nafarelin.

    In plain wordsIn women, higher-dose nafarelin produced fewer bleeding days than lower-dose nafarelin.

    Peptide
    Nafarelin
    Outcome
    DecreaseBleeding days
    Study

    n: not reported in source

    Comparator
    125 micrograms daily nafarelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    250 micrograms daily · intranasal · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    With the higher dose of nafarelin acetate there were significantly fewer bleeding episodes, less number of days of bleeding, and longer cycles.
    2 context sentences
    Summary · context
    A group of 24 women with normal menstrual cycles were treated with nafarelin acetate administered in doses of either 125 micrograms or 250 micrograms daily intranasally for 6 months.
    Summary · context
    Each subject was studied for one ovulatory control cycle, six treatment cycles, and post-treatment until the return of ovulation was documented.
  11. 11HumanNon-randomized trialEfficacy outcome

    In women, higher-dose nafarelin produced significantly longer cycles than lower-dose nafarelin.

    In plain wordsIn women, higher-dose nafarelin produced longer cycles than lower-dose nafarelin.

    Peptide
    Nafarelin
    Outcome
    IncreaseCycle length
    Study

    n: not reported in source

    Comparator
    125 micrograms daily nafarelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    250 micrograms daily · intranasal · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    With the higher dose of nafarelin acetate there were significantly fewer bleeding episodes, less number of days of bleeding, and longer cycles.
    2 context sentences
    Summary · context
    A group of 24 women with normal menstrual cycles were treated with nafarelin acetate administered in doses of either 125 micrograms or 250 micrograms daily intranasally for 6 months.
    Summary · context
    Each subject was studied for one ovulatory control cycle, six treatment cycles, and post-treatment until the return of ovulation was documented.
  12. 12HumanNon-randomized trialEfficacy outcome

    In women, LH area under the curve was significantly lower with higher-dose nafarelin than lower-dose nafarelin.

    In plain wordsIn women, LH area under the curve was lower with higher-dose nafarelin than lower-dose nafarelin.

    Peptide
    Nafarelin
    Outcome
    DecreaseLH area under curve
    Study

    n: not reported in source

    Comparator
    125 micrograms daily nafarelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    250 micrograms daily · intranasal · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    During the treatment phase the area under the LH curve was significantly less and the acute response of LH in the last week of treatment was significantly less with the higher dose of drug.
    2 context sentences
    Summary · context
    A group of 24 women with normal menstrual cycles were treated with nafarelin acetate administered in doses of either 125 micrograms or 250 micrograms daily intranasally for 6 months.
    Summary · context
    Each subject was studied for one ovulatory control cycle, six treatment cycles, and post-treatment until the return of ovulation was documented.
  13. 13HumanNon-randomized trialEfficacy outcome

    In women, the final-week acute LH response was significantly lower with higher-dose nafarelin than lower-dose nafarelin.

    In plain wordsIn women, the final-week acute LH response was lower with higher-dose nafarelin than lower-dose nafarelin.

    Peptide
    Nafarelin
    Outcome
    DecreaseAcute LH response in last week
    Study

    n: not reported in source

    Comparator
    125 micrograms daily nafarelin
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    250 micrograms daily · intranasal · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    During the treatment phase the area under the LH curve was significantly less and the acute response of LH in the last week of treatment was significantly less with the higher dose of drug.
    2 context sentences
    Summary · context
    A group of 24 women with normal menstrual cycles were treated with nafarelin acetate administered in doses of either 125 micrograms or 250 micrograms daily intranasally for 6 months.
    Summary · context
    Each subject was studied for one ovulatory control cycle, six treatment cycles, and post-treatment until the return of ovulation was documented.
  14. 14HumanNon-randomized trialEfficacy outcome

    In women receiving either nafarelin dose, acute LH responses were lower on days 98 and 186 than on day 1.

    In plain wordsIn women receiving either nafarelin dose, acute LH responses were lower on days 98 and 186 than on day 1.

    Peptide
    Nafarelin
    Outcome
    DecreaseAcute LH response over treatment
    Study

    n: not reported in source

    Comparator
    day 1 acute response
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    125 or 250 micrograms daily · intranasal · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    With both doses of nafarelin acetate the acute responses of LH, FSH and estradiol were significantly greater on day 1 than on either day 98 or day 186.
    2 context sentences
    Summary · context
    A group of 24 women with normal menstrual cycles were treated with nafarelin acetate administered in doses of either 125 micrograms or 250 micrograms daily intranasally for 6 months.
    Summary · context
    Each subject was studied for one ovulatory control cycle, six treatment cycles, and post-treatment until the return of ovulation was documented.
  15. 15HumanNon-randomized trialEfficacy outcome

    In women receiving either nafarelin dose, acute FSH responses were lower on days 98 and 186 than on day 1.

    In plain wordsIn women receiving either nafarelin dose, acute FSH responses were lower on days 98 and 186 than on day 1.

    Peptide
    Nafarelin
    Outcome
    DecreaseAcute FSH response over treatment
    Study

    n: not reported in source

    Comparator
    day 1 acute response
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    125 or 250 micrograms daily · intranasal · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    With both doses of nafarelin acetate the acute responses of LH, FSH and estradiol were significantly greater on day 1 than on either day 98 or day 186.
    2 context sentences
    Summary · context
    A group of 24 women with normal menstrual cycles were treated with nafarelin acetate administered in doses of either 125 micrograms or 250 micrograms daily intranasally for 6 months.
    Summary · context
    Each subject was studied for one ovulatory control cycle, six treatment cycles, and post-treatment until the return of ovulation was documented.
  16. 16HumanNon-randomized trialEfficacy outcome

    In women receiving either nafarelin dose, acute estradiol responses were lower on days 98 and 186 than on day 1.

    In plain wordsIn women receiving either nafarelin dose, estradiol responses were lower on days 98 and 186 than on day 1.

    Peptide
    Nafarelin
    Outcome
    DecreaseAcute estradiol response over treatment
    Study

    n: not reported in source

    Comparator
    day 1 acute response
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    125 or 250 micrograms daily · intranasal · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    With both doses of nafarelin acetate the acute responses of LH, FSH and estradiol were significantly greater on day 1 than on either day 98 or day 186.
    2 context sentences
    Summary · context
    A group of 24 women with normal menstrual cycles were treated with nafarelin acetate administered in doses of either 125 micrograms or 250 micrograms daily intranasally for 6 months.
    Summary · context
    Each subject was studied for one ovulatory control cycle, six treatment cycles, and post-treatment until the return of ovulation was documented.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.